SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending sharply higher following news of an award under the SHIELD program, which the community is buzzing about as "Golden Dome" news, signaling a significant validation and opening for government contracts. This development is fueling extreme bullish sentiment among longs, who see it as "just the beginning" for the direct-to-mobile satellite firm, while igniting further debate from critics questioning its pre-revenue valuation.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending following its shareholder meeting, where a significant increase in authorized shares was approved alongside an unexpected $200 million equity investment in MrBeast's 'Beast Industries'. Community discussion is highly polarized, with many expressing deep concern over potential shareholder dilution and questioning management's strategic focus away from its core Ethereum treasury. While some see the MrBeast deal as a bold move for broader reach, critics view it as an unprofessional diversion that complicates the company's financial outlook.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd (SPHL) is trending due to an explosive multi-day rally, largely fueled by its ultra-low share float and a recent solar partnership catalyst. The community is actively discussing massive percentage gains, a potential short squeeze, and comparing SPHL to other high-volatility microcap runners. Traders are keenly observing for continued price action and managing positions amidst significant intraday swings.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials (RGNT) is trending following recent patent news for its GelrinC liquid formulation and its status as a newly public company. The community is buzzing about its low float and insider lock-up, speculating on its potential for a significant short squeeze as interest grows.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is surging after reporting strong earnings, exceeding expectations and forecasting significant capital expenditure to meet escalating AI chip demand. The company's optimistic outlook on the enduring AI megatrend, alongside a new US-Taiwan trade agreement to expand domestic chip manufacturing, is a major talking point driving positive sentiment across the semiconductor sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending due to a significant partnership with World Liberty Financial for USD1 payroll and card integration, which the community views as a major development for its real-world utility. Enthusiastic discussions also center on Zebec's ISO 20022 and MiCA compliance, alongside upcoming announcements for a Super App launch and potential integrations with major networks like Stellar and Ripple, fueling strong bullish sentiment for its long-term potential in payment infrastructure.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is experiencing intense trading interest following its 1-for-15 reverse stock split, which created an ultra-low float. The community is actively discussing the stock's potential for a massive short squeeze, drawing comparisons to other micro-cap runners and anticipating explosive gains as the company works towards Nasdaq compliance.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following a significant multi-year defense contract with Sweden, marking its third major international government deal for satellite services within the last year and substantially boosting its contract backlog. The community is actively celebrating impressive gains, discussing the company's growing institutional ownership, Google's involvement with Project Suncatcher, and its strategic position within the rapidly expanding space intelligence sector. While many see substantial long-term potential, some caution about the rapid appreciation and potential for a near-term consolidation.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma (FIG) is trending as it continues to experience significant downward pressure, dipping below its initial public offering price, which many in the community attribute to ongoing insider selling and upcoming lockup expirations. This downturn has sharply divided investors, with some viewing it as a generational buying opportunity due to perceived undervaluation and strong product adoption, while others express deep concern over its financial performance and the long-term impact of AI on the UI/UX design sector.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as its stock continues to hit new all-time lows, intensifying community debate around the company's financial stability and leadership. Many express frustration over persistent dilution fears and the interim CEO's performance, questioning the long-term viability despite a highly praised vehicle product and anticipation for upcoming production and delivery figures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.read more...

How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?

Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.

<ul class="summary-bullets"><li>Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears.</li><li>Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.</li><li>Novo recently lost out to Pfizer in the bidding war for smaller obesity drugmaker Metsera but completed its acquisition of Akero therapeutics in December.</li></ul>Shares of obesity drugmaker Viking Therapeutics (VKTX) rallied 17% on Wednesday after Denmark-based Wegovy producer Novo Nordisk (NVO) said it is on the lookout for merger and acquisition deals to boost its drug portfolio.Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio.Other obesity drug manufacturing stocks also rallied at the time of writing, including Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR). <a href="https://stocktwits.com/symbol/TERN">TERN shares</a> rose 10% at the time of writing while <a href="https://stocktwits.com/symbol/GPCR">GPCR stock</a> rose 6%.<h2 class="st-heading-2">Novo’s Recent Acquisition Attempts</h2>Doustdar said that the company can afford any amount for an asset, provided it is worth it. Talking about Novo Nordisk’s recent $10 billion bid to acquire smaller obesity drug maker Metsera, the CEO said, “We stopped at $10 billion in Metsera because to us, it was not worth a penny more.” Novo <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-eyes-big-push-towards-obesity-drug-development-in-2026/cmUafq6R4ED">lost out to Pfizer</a> in the bidding war.However, in December, Novo completed its acquisition of Akero Therapeutics for up to $5.2 billion in a bid to gain access to its experimental drug Efruxifermin, being developed for the treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).<h2 class="st-heading-2">Viking’s Obesity Pipeline</h2>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The company is also studying a tablet formulation of the drug.Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears."I think the interest is probably broader than is visible. I think that there are more parties sort of circling around the space and very intrigued," Lian said while adding that he thinks there is a "fair amount of interest” across the industry.Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.“...having a larger party involved would be, you know, very helpful in driving the program through commercialization,” he said. “That said, I don't think it's mandatory. I think it's probably a preference, but it's not mandatory. We're prepared to go alone, but we're also prepared to engage with anybody who's interested.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VKTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that Novo might buy Viking for about $10 billion, representing massive upside from its current near $4 billion market cap.<stembedurl>https://www.stocktwits.com/CPA_/message/641819411</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-bear-says-new-fsd-subscription-model-proves-the-tech-is-not-an-asset/cmULNffR4eU">Tesla Bear Says New FSD Subscription Model Proves The Tech Is Not An Asset: Retail Echoes Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 

Equity

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 


VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4% - What's Next?

Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4% - Here's What Happened...

LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?

LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.

Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Osaic Holdings Inc. raised its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 101.9% in the 2nd quarter, according to its most recent Form 13F filing with the...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are presently covering the stock...

Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% - Here's Why

Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% - Here's Why...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.38	--	--	N/A
Q3 '25	-$0.38	-$0.37	1.40%	BEAT
Q2 '25	-$0.34	-$0.36	-5.04%	MISSED
Q1 '25	-$0.26	--	--	N/A
Q4 '24	-$0.21	--	--	N/A

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR